随着肿瘤靶向治疗研究的不断深入,肿瘤相关的分子标记也逐渐成为研究的前沿和热点。结肠癌转移相关基因1(metastasis-associated in colon cancer-1,MACC1)是对人类结肠癌组织、转移组织和正常组织进行全基因组扫描而发现的一个新基因...随着肿瘤靶向治疗研究的不断深入,肿瘤相关的分子标记也逐渐成为研究的前沿和热点。结肠癌转移相关基因1(metastasis-associated in colon cancer-1,MACC1)是对人类结肠癌组织、转移组织和正常组织进行全基因组扫描而发现的一个新基因。最近研究发现MACC1与其他肿瘤的发生发展关系也十分密切,可能成为肿瘤治疗的新的分子靶点。为了对MACC1的功能有一个全面的认识和了解,在本综述中,我们分析了MACC1的结构、MACC1与肿瘤发生发展之间的关系、MACC1与肿瘤转移之间的关系以及其在调控信号途径中的作用。展开更多
In recent years,many significant advances have been made on molecular target therapy to aim directly at epidermal growth factor receptors and vascular endothelial growth factor in breast cancers.Clinical studies of su...In recent years,many significant advances have been made on molecular target therapy to aim directly at epidermal growth factor receptors and vascular endothelial growth factor in breast cancers.Clinical studies of such agents as trastuzumab,lapatinib,erlotinib and bevacituzumab have been widely conducted.This paper will review the recent research progress related to targeted therapy.展开更多
Prostate cancer （PCa） incidence and mortality have decreased in recent years. Nonetheless, it remains one of the most prevalent cancers in men, being a disquieting cause of men＇s death worldwide. Changes in many ce...Prostate cancer （PCa） incidence and mortality have decreased in recent years. Nonetheless, it remains one of the most prevalent cancers in men, being a disquieting cause of men＇s death worldwide. Changes in many cell signaling pathways have a predominant role in the onset, development, and progression of the disease. These include prominent pathways involved in the growth, apoptosis, and angiogenesis of the normal prostate gland, such as an- drogen and estrogen signaling, and other growth factor signaling pathways. Understanding the foundations of PCa is leading to the discovery of key molecules that could be used to improve patient management. The ideal scenario would be to have a panel of molecules, preferably detectable in body fluids, that are specific and sensitive biomarkers for PCa In the early stages, androgen deprivation is the gold standard therapy. However, as the cancer progresses, it even- tually becomes independent of androgens, and hormonal therapy fails. For this reason, androgen-independent PCa is still a major therapeutic challenge. By disrupting specific protein interactions or manipulating the expression of some key molecules, it might be possible to regulate tumor growth and metastasis formation, avoiding the systemic side effects of current therapies. Clinical trials are already underway to assess the efficacy of molecules specially designed to target key proteins or protein interactions. In this review, we address that recent progress made towards under- standing PCa development and the molecular pathways underlying this pathology. We also discuss relevant molecular markers for the management of PCa and new therapeutic challenges.展开更多
文摘随着肿瘤靶向治疗研究的不断深入,肿瘤相关的分子标记也逐渐成为研究的前沿和热点。结肠癌转移相关基因1(metastasis-associated in colon cancer-1,MACC1)是对人类结肠癌组织、转移组织和正常组织进行全基因组扫描而发现的一个新基因。最近研究发现MACC1与其他肿瘤的发生发展关系也十分密切,可能成为肿瘤治疗的新的分子靶点。为了对MACC1的功能有一个全面的认识和了解,在本综述中,我们分析了MACC1的结构、MACC1与肿瘤发生发展之间的关系、MACC1与肿瘤转移之间的关系以及其在调控信号途径中的作用。
文摘In recent years,many significant advances have been made on molecular target therapy to aim directly at epidermal growth factor receptors and vascular endothelial growth factor in breast cancers.Clinical studies of such agents as trastuzumab,lapatinib,erlotinib and bevacituzumab have been widely conducted.This paper will review the recent research progress related to targeted therapy.
基金Project supported by Fundao para a Ciência e Tecnologia(FCT)(PTDC/QUI-BIQ/118492/2010)Fundo Europeu de Desenvol-vimento Regional(FEDER)(FCOMP-01-0124-FEDER-020895),Portugal
文摘Prostate cancer （PCa） incidence and mortality have decreased in recent years. Nonetheless, it remains one of the most prevalent cancers in men, being a disquieting cause of men＇s death worldwide. Changes in many cell signaling pathways have a predominant role in the onset, development, and progression of the disease. These include prominent pathways involved in the growth, apoptosis, and angiogenesis of the normal prostate gland, such as an- drogen and estrogen signaling, and other growth factor signaling pathways. Understanding the foundations of PCa is leading to the discovery of key molecules that could be used to improve patient management. The ideal scenario would be to have a panel of molecules, preferably detectable in body fluids, that are specific and sensitive biomarkers for PCa In the early stages, androgen deprivation is the gold standard therapy. However, as the cancer progresses, it even- tually becomes independent of androgens, and hormonal therapy fails. For this reason, androgen-independent PCa is still a major therapeutic challenge. By disrupting specific protein interactions or manipulating the expression of some key molecules, it might be possible to regulate tumor growth and metastasis formation, avoiding the systemic side effects of current therapies. Clinical trials are already underway to assess the efficacy of molecules specially designed to target key proteins or protein interactions. In this review, we address that recent progress made towards under- standing PCa development and the molecular pathways underlying this pathology. We also discuss relevant molecular markers for the management of PCa and new therapeutic challenges.
